Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment

被引:4
|
作者
Dedemadi, Anastasia-Georgia [1 ,2 ]
Gkolfinopoulou, Christina [1 ]
Nikoleri, Dimitra [3 ,4 ]
Nikoloudaki, Myrto [3 ]
Ruhanen, Hanna [5 ,6 ,7 ]
Holopainen, Minna [5 ,6 ,7 ]
Kakela, Reijo [6 ,7 ]
Christopoulou, Georgia [8 ]
Bournazos, Stavros [8 ]
Constantoulakis, Pantelis [8 ]
Sidiropoulos, Prodromos [3 ,4 ]
Bertsias, George [3 ,4 ]
Chroni, Angeliki [1 ]
机构
[1] Natl Ctr Sci Res Demokritos, Inst Biosci & Applicat, Athens 15341, Greece
[2] Natl & Kapodistrian Univ Athens, Dept Chem, Athens, Greece
[3] Univ Crete, Med Sch, Lab Rheumatol Autoimmun & Inflammat, Iraklion, Greece
[4] FORTH, Inst Mol Biol & Biotechnol, Iraklion, Greece
[5] Univ Helsinki, Helsinki Inst Life Sci, Lipid Unit, HiLIPID, Helsinki, Finland
[6] Bioctr Finland, Helsinki, Finland
[7] Univ Helsinki, Fac Biol & Environm Sci, Mol & Integrat Biosci Res Program, Helsinki, Finland
[8] Genotypos Sci Labs, Athens, Greece
关键词
systemic lupus erythematosus; biologicals; high-density lipoprotein; atheroprotection; lipidomic profile; CHOLESTEROL EFFLUX CAPACITY; ATHEROSCLEROSIS; FUNCTIONALITY;
D O I
10.1093/rheumatology/keae192
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Chronic inflammatory diseases, like Systemic Lupus Erythematosus (SLE), carry an increased risk for atherosclerosis and cardiovascular events, accompanied by impairment of atheroprotective properties of high-density lipoprotein (HDL). In SLE, serum B cell-activating factor (BAFF), a cytokine implicated in disease progression, has been correlated with subclinical atherosclerosis. We investigated the impact of treatment with belimumab -an anti-BAFF monoclonal antibody- on HDL atheroprotective properties and composition in SLE patients.Methods Serum samples were collected from 35 SLE patients with active disease despite conventional therapy, before and after 6-month add-on treatment with belimumab, and 26 matched healthy individuals. We measured cholesterol efflux and antioxidant capacities, paraoxonase-1 (PON1) activity, serum amyloid A1 (SAA1), myeloperoxidase (MPO) and lipid peroxidation product levels of HDL. LC-MS/MS was performed to analyse the HDL lipidome.Results Following treatment with belimumab, cholesterol efflux and antioxidant capacities of HDL were significantly increased in SLE patients and restored to levels of control subjects. HDL-associated PON1 activity was also increased, whereas lipid peroxidation products were decreased following treatment. HDL cholesterol efflux and antioxidant capacities correlated negatively with the disease activity. Changes were noted in the HDL lipidome of SLE patients following belimumab treatment, as well as between SLE patients and healthy individuals, and specific changes in lipid species correlated with functional parameters of HDL.Conclusions HDL of SLE patients with active disease displays impaired atheroprotective properties accompanied by distinct lipidomic signatures compared with controls. Belimumab treatment may improve the HDL atheroprotective properties and modify the HDL lipidomic signature in SLE patients, thus potentially mitigating atherosclerosis development. Graphical Abstract
引用
收藏
页数:10
相关论文
共 50 条
  • [1] High-density lipoprotein functionality in systemic lupus erythematosus
    Ganjali, Shiva
    Shirmohammadi, Leila
    Read, Morgayn, I
    Sahebkar, Amirhossein
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2020, 50 (04) : 769 - 775
  • [2] IMPROVEMENT OF BELIMUMAB ON QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Yi, G.
    Zheng, S.
    Guo, X.
    Liu, M.
    Li, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1351 - 1351
  • [3] Belimumab for the treatment of systemic lupus erythematosus
    Jordan, Natasha
    D'Cruz, David P.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (02) : 195 - 204
  • [4] Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis
    McMahon, Maureen
    Grossman, Jennifer
    FitzGerald, John
    Dahlin-Lee, Erika
    Wallace, Daniel J.
    Thong, Bernard Y.
    Badsha, Humeira
    Kalunian, Kenneth
    Charles, Christina
    Navab, Mohamad
    Fogelman, Alan M.
    Hahn, Bevra H.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (08): : 2541 - 2549
  • [5] ABNORMALITY OF HIGH-DENSITY LIPOPROTEIN SUBCLASS DISTRIBUTION IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    ETTINGER, WH
    APPLEBAUMBOWDEN, D
    GOLDBERG, AP
    HAZZARD, WR
    CLINICAL RESEARCH, 1985, 33 (02): : A518 - A518
  • [6] High-density lipoprotein: Is it always atheroprotective?
    Ansell B.J.
    Fonarow G.C.
    Fogelman A.M.
    Current Atherosclerosis Reports, 2006, 8 (5) : 405 - 411
  • [7] Steroid-loaded reconstituted high-density lipoprotein nanocarrier: A new treatment for systemic lupus erythematosus
    Yu, Ye
    Liu, Xuesong
    Ma, Xinyi
    Jiang, Gan
    Song, Qingxiang
    Guo, Ruru
    Wang, Suli
    Gao, Xiaoling
    Lu, Liangjing
    JOURNAL OF BIOMATERIALS APPLICATIONS, 2023, 37 (09) : 1542 - 1554
  • [8] Antibodies toward high-density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus
    Batuca, J. R.
    Ames, P. R. J.
    Isenberg, D. A.
    Alves, J. Delgado
    AUTOIMMUNITY, PT D: AUTOIMMUNE DISEASE, ANNUS MIRABILIS, 2007, 1108 : 137 - 146
  • [9] The safety of belimumab for the treatment of systemic lupus erythematosus
    Wise, Leanna M.
    Stohl, William
    EXPERT OPINION ON DRUG SAFETY, 2019, 18 (12) : 1133 - 1144
  • [10] Subcutaneous belimumab in the treatment of systemic lupus erythematosus
    Elalouf, Ofir
    Keeling, Stephanie O.
    Touma, Zahi
    IMMUNOTHERAPY, 2018, 10 (13) : 1163 - 1173